Although
Danhong injection (DHI) is the most widely prescribed Chinese medicine for both
stroke and
coronary artery disease (CAD), its underlying common molecular mechanisms remain unclear. An integrated network pharmacology and experimental verification approach was used to decipher common pharmacological mechanisms of DHI on
stroke and CAD treatment. A compound-target-disease & function-pathway network was constructed and analyzed, indicating that 37 ingredients derived from DH (Salvia miltiorrhiza Bge.,
Flos Carthami tinctorii and DHI) modulated 68 common targets shared by
stroke and CAD. In-depth network analysis results of the top diseases, functions, pathways and upstream regulators implied that a common underlying mechanism linking DHI's role in
stroke and CAD treatment was inflammatory response in the process of
atherosclerosis. Experimentally, DHI exerted comprehensive anti-inflammatory effects on LPS,
ox-LDL or
cholesterol crystal-induced NF-κB, c-jun and p38 activation, as well as IL-1β, TNF-α, and IL-10 secretion in vascular endothelial cells. Ten of 14 predicted ingredients were verified to have significant anti-inflammatory activities on LPS-induced endothelial
inflammation. DHI exerts pharmacological efficacies on both
stroke and CAD through multi-ingredient, multi-target, multi-function and multi-pathway mode. Anti-endothelial
inflammation therapy serves as a common underlying mechanism. This study provides a new understanding of DHI in clinical application on cardiovascular and
cerebrovascular diseases.